CLINICAL TRIALS PROFILE FOR METOPIRONE
✉ Email this page to a colleague
All Clinical Trials for METOPIRONE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00567814 ↗ | A Placebo-Controlled Study of a Combination of Metyrapone and Oxazepam in Cocaine Addiction | Completed | Embera NeuroTherapeutics, Inc. | N/A | 2007-12-01 | Subjects will be randomly assigned to receive either one of the two potential dose combinations of the study medications or placebo over 6 weeks. The study will include twice weekly visits to the research clinic for laboratory studies, safety assessments and urine drug screens. Subjects will also be questioned regarding drug craving and mood symptoms. |
| NCT01673087 ↗ | Stress Biomarkers:Attaching Biological Meaning to Field Friendly Salivary Measures | Completed | University of Michigan | Phase 1 | 2012-10-01 | Cortisol is a stress hormone that can be measured in saliva. This has provided a convenient way to evaluate the biological impact of day-to-day stressors that people encounter as they go about their lives, since saliva is so easy to collect. However, the biological meaning of saliva cortisol measures has never been carefully examined. The goal of this study is to collect saliva from a large group of people as they go about their every-day lives, to measure their cortisol levels, and then study them in the laboratory where Investigators can learn more about how their stress response system (which produces cortisol) is really functioning. Investigators can then determine much more precisely what saliva cortisol levels really mean in terms of stress system biology. This will allow investigators to obtain much more useful information from the next decade of research on naturalistic stress and its biological impact using saliva cortisol measures, helping investigators to understand how stress undermines health and how to combat this effect. |
| NCT02297945 ↗ | Effects of Metyrapone in Patients With Endogenous Cushing's Syndrome | Completed | HRA Pharma | Phase 3 | 2015-04-01 | The purpose of this prospective, international phase III/IV study is to assess the efficacy and safety of metyrapone in patients with endogenous Cushing's syndrome during up to 36 weeks of treatment. The ability of metyrapone (250 mg capsules) to normalize urinary free cortisol (UFC) levels will be assessed during up to 36 weeks (9 months) of treatment. |
| NCT02856854 ↗ | A Study of Metyrapone and Oxazepam Combination Product (EMB-001) and Cocaine | Completed | National Institute on Drug Abuse (NIDA) | Phase 1 | 2016-07-01 | EMB-001 is a combination of 2 drugs: the cortisol synthesis inhibitor, metyrapone (Metopirone®), and the benzodiazepine receptor agonist, oxazepam (original trade name Serax®; now marketed as oxazepam (generic) only). This Phase 1b cocaine interaction study is being conducted in order to assess the safety and PK of EMB-001 and cocaine in combination. |
| NCT02856854 ↗ | A Study of Metyrapone and Oxazepam Combination Product (EMB-001) and Cocaine | Completed | Embera NeuroTherapeutics, Inc. | Phase 1 | 2016-07-01 | EMB-001 is a combination of 2 drugs: the cortisol synthesis inhibitor, metyrapone (Metopirone®), and the benzodiazepine receptor agonist, oxazepam (original trade name Serax®; now marketed as oxazepam (generic) only). This Phase 1b cocaine interaction study is being conducted in order to assess the safety and PK of EMB-001 and cocaine in combination. |
| NCT04501874 ↗ | A Study to Evaluate EMB 001 in Subjects With Cocaine Use Disorder | Recruiting | National Institute on Drug Abuse (NIDA) | Phase 2 | 2020-07-29 | EMB-001 is a combination of 2 drugs: the cortisol synthesis inhibitor, metyrapone (Metopirone®), and the benzodiazepine receptor agonist, oxazepam (original trade name Serax®; now marketed as oxazepam (generic) only). This is a Phase 2 study in approximately 80 adult subjects with moderate-to-severe Cocaine Use Disorder (CUD). |
| NCT04501874 ↗ | A Study to Evaluate EMB 001 in Subjects With Cocaine Use Disorder | Recruiting | Embera NeuroTherapeutics, Inc. | Phase 2 | 2020-07-29 | EMB-001 is a combination of 2 drugs: the cortisol synthesis inhibitor, metyrapone (Metopirone®), and the benzodiazepine receptor agonist, oxazepam (original trade name Serax®; now marketed as oxazepam (generic) only). This is a Phase 2 study in approximately 80 adult subjects with moderate-to-severe Cocaine Use Disorder (CUD). |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for METOPIRONE
Condition Name
Clinical Trial Locations for METOPIRONE
Trials by Country
Clinical Trial Progress for METOPIRONE
Clinical Trial Phase
Clinical Trial Sponsors for METOPIRONE
Sponsor Name
